What is the half-life of phenobarbital (barbiturate)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The half-life of phenobarbital in infants is approximately 20-133 hours, in children it is around 37-73 hours, and in neonates it can range from 45-500 hours. This significant variation in half-life is crucial to consider in clinical practice, as it affects the timing of brain death examinations and the interpretation of neurologic tests [ 1 ]. The half-life of phenobarbital is influenced by various factors, including age, liver function, and renal function, which can impact the drug's metabolism and elimination [ 1 ].

Key Considerations

  • The half-life of phenobarbital is longer in neonates compared to infants and children, which may require adjustments in dosing and timing of brain death examinations [ 1 ].
  • The elimination half-life of phenobarbital does not guarantee therapeutic drug levels, and drug levels should be obtained to ensure that levels are in a low to mid therapeutic range prior to neurologic examination [ 1 ].
  • Physicians should be aware of the total amounts of administered medication that can affect drug metabolism and levels, and consider the potential for drug interactions due to the prolonged half-life of phenobarbital [ 1 ].

Clinical Implications

  • The prolonged half-life of phenobarbital requires careful consideration in clinical practice, particularly in the context of brain death examinations and the interpretation of neurologic tests [ 1 ].
  • The significant variation in half-life among different age groups highlights the importance of individualized dosing and monitoring in pediatric patients [ 1 ].

From the FDA Drug Label

In adults, the plasma half-life of phenobarbital is 53 to 118 hours (mean 79 hours) and in children/newborns, the plasma half-life is 60 to 180 hours (mean 110 hours). The half-life of phenobarbital is 53 to 118 hours (mean 79 hours) in adults and 60 to 180 hours (mean 110 hours) in children/newborns 2.

From the Research

Half Life of Phenobarbital

  • The half-life of phenobarbital is approximately 5.8 days after an intravenous dose and 5.1 days after an oral dose, as reported in a study published in the Journal of Clinical Pharmacology 3.
  • The elimination half-life of phenobarbital can vary depending on the individual and the dosage form, but 5-6 days is a commonly cited range.
  • Other studies have not specifically reported on the half-life of phenobarbital, but have discussed its pharmacokinetics and efficacy in treating epilepsy 4, 5, 6, 7.

Factors Affecting Half Life

  • The half-life of phenobarbital can be influenced by factors such as liver function, kidney function, and drug interactions.
  • However, the exact impact of these factors on the half-life of phenobarbital is not well understood and requires further study.

Clinical Significance

  • Understanding the half-life of phenobarbital is important for determining the optimal dosage and frequency of administration in patients with epilepsy.
  • The half-life of phenobarbital can also impact the risk of adverse effects, such as sedation and cognitive impairment, which are commonly associated with this medication 7.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Phenobarbital pharmacokinetics and bioavailability in adults.

Journal of clinical pharmacology, 1982

Research

Side effects of phenobarbital in epilepsy: a systematic review.

Epileptic disorders : international epilepsy journal with videotape, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.